LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 2 | M02 | 72 | hr | 1401 | 2526 | 4223 | 0.5981 | 0.3985 |
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 3 | M02 | 72 | hr | 1401 | 2302 | 4223 | 0.5451 | 0.3191 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 1 | O08 | 72 | hr | 1401 | 4738 | 4223 | 1.1219 | 1.1825 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 2 | O08 | 72 | hr | 1401 | 3765 | 4223 | 0.8915 | 0.8377 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 3 | O08 | 72 | hr | 1401 | 3617 | 4223 | 0.8565 | 0.7852 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 1 | J20 | 72 | hr | 1401 | 1740 | 4223 | 0.4120 | 0.1200 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 2 | J20 | 72 | hr | 1401 | 1610 | 4223 | 0.3812 | 0.0739 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 3 | J20 | 72 | hr | 1401 | 1944 | 4223 | 0.4603 | 0.1923 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 1 | M08 | 72 | hr | 1401 | 1852 | 4223 | 0.4385 | 0.1597 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 2 | M08 | 72 | hr | 1401 | 1511 | 4223 | 0.3578 | 0.0388 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 3 | M08 | 72 | hr | 1401 | 1506 | 4223 | 0.3566 | 0.0370 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 1 | P14 | 72 | hr | 1401 | 3837 | 4223 | 0.9086 | 0.8632 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 2 | P14 | 72 | hr | 1401 | 4146 | 4223 | 0.9818 | 0.9727 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 3 | P14 | 72 | hr | 1401 | 4431 | 4223 | 1.0492 | 1.0737 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 1 | H02 | 72 | hr | 1401 | 999 | 4223 | 0.2366 | -0.1427 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 2 | H02 | 72 | hr | 1401 | 978 | 4223 | 0.2316 | -0.1501 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 3 | H02 | 72 | hr | 1401 | 1182 | 4223 | 0.2799 | -0.0778 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 1 | L20 | 72 | hr | 1401 | 1406 | 4223 | 0.3329 | 0.0016 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 2 | L20 | 72 | hr | 1401 | 1448 | 4223 | 0.3429 | 0.0165 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 3 | L20 | 72 | hr | 1401 | 1415 | 4223 | 0.3351 | 0.0048 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 1 | H08 | 72 | hr | 1401 | 1353 | 4223 | 0.3204 | -0.0172 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 2 | H08 | 72 | hr | 1401 | 1369 | 4223 | 0.3242 | -0.0115 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 3 | H08 | 72 | hr | 1401 | 1464 | 4223 | 0.3467 | 0.0221 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 1 | G08 | 72 | hr | 1401 | 1109 | 4223 | 0.2626 | -0.1037 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 2 | G08 | 72 | hr | 1401 | 1241 | 4223 | 0.2939 | -0.0569 |